Skip to main content Skip to footer

Serious shortage protocols (SSPs)

The endorsement requirements for products supplied in accordance with a Serious Shortage Protocol (SSP) have been updated, as per Clause 9E, Part II of the June 2021 Drug Tariff

More information is available in our 'Updated endorsement guidance for SSP products' news article.

In February 2019, the Human Medicines Regulations 2012 were changed to introduce SSPs.

 

Further changes came into force in July 2019, in the NHS (amendments relating to serious shortage protocols) Regulations 2019.

 

If the Department of Health and Social Care (DHSC) decide there is a serious shortage of a specific medicine or appliance, then an SSP may be issued.

 

The contractor must use their professional skill and judgement to decide, alongside medical experts, whether it's reasonable and appropriate to substitute the patient's prescribed order for the active SSP. The patient would also have to agree to the alternative supply for that dispensing month.

 

Contractors should check the table for the latest information for each SSP's validity, as they can change. 

 

Active SSPs
 

Name of SSP \ ref no. Start and end date Supporting guidance
SSP034 Combisal® 125mcg/25mcg inhalers (PDF:146KB) 22 Jul 2022 to 19 Aug 2022 Combisal® 125mcg/25mcg inhalers supporting guidance plus Q&A (PDF:153KB)
SSP033 Paracetamol 120mg suppositories (PDF:139KB) 31 May 2022 to 26 Aug 2022 Paracetamol 120mg suppositories supporting guidance plus Q&A (PDF:111KB)
SSP032 Atorvastatin (Lipitor®) 10mg chewable tablets (PDF:145KB) 31 May 2022 to 12 Aug 2022 Atorvastatin (Lipitor®) 10mg chewable tablets supporting guidance plus Q&A (PDF:117KB)
SSP031 Estradiol (Sandrena®) 0.5mg and 1mg gel sachets substitution and restriction (PDF:751KB)

19 May 2022 to 19 Aug 2022

This SSP has been varied – the revised date is now 28 October 2022

Sandrena® supporting guidance plus Q&A (PDF:185KB)
SSP030 Estradiol (Sandrena®) 0.5mg and 1mg gel sachets substitution (PDF:751KB)

19 May 2022 to 19 Aug 2022

This SSP has been varied – the revised date is now 28 October 2022

Sandrena® supporting guidance plus Q&A (PDF:183KB)
SSP029 Estradiol (Sandrena®) 0.5mg and 1mg gel sachets restriction (PDF:600KB)

19 May 2022 to 19 Aug 2022

This SSP has been varied – the revised date is now 28 October 2022

Sandrena® supporting guidance plus Q&A (PDF:130KB)
SSP028 Estradiol (Lenzetto®)1.53mg/dose transdermal spray substitution and restriction (PDF:749KB)

19 May 2022 to 19 Aug 2022

This SSP has been varied – the revised date is now 28 October 2022

Lenzetto® supporting guidance plus Q&A (PDF:147KB)
SSP027 Estradiol (Lenzetto®)1.53mg/dose transdermal spray substitution (PDF:748KB)

19 May 2022 to 19 Aug 2022

This SSP has been varied – the revised date is now 28 October 2022

Lenzetto® supporting guidance plus Q&A (PDF:146KB)
SSP026 Estradiol (Lenzetto®)1.53mg/dose transdermal spray restriction (PDF:601KB)

19 May 2022 to 19 Aug 2022

This SSP has been varied – the revised date is now 28 October 2022

Lenzetto® supporting guidance plus Q&A (PDF:128KB)
SSP025 Estriol  (Ovestin® 1mg cream) 0.1% cream substitution and restriction (PDF:228KB)

19 May 2022 to 19 Aug 2022

This SSP has been varied – the revised date is now 28 October 2022

Please note that the dose equivalence advice and endorsement guidance for this SSP have been updated, 28/7/22

Ovestin® supporting guidance plus Q&A (PDF:152KB)
SSP024 Estriol  (Ovestin® 1mg cream) 0.1% cream substitution (PDF:226KB)

19 May 2022 to 19 Aug 2022

This SSP has been varied – the revised date is now 28 October 2022

Please note that the dose equivalence advice and endorsement guidance for this SSP have been updated, 28/7/22

Ovestin® supporting guidance plus Q&A (PDF:133KB)
SSP023 Estradiol (Oestrogel® Pump-Pack 0.06% gel) 0.06% gel (750microgram per actuation) substitution and restriction (PDF:751KB)

19 May 2022 to 19 Aug 2022

This SSP has been varied – the revised date is now 28 October 2022

Oestrogel® supporting guidance plus Q&A (PDF:150KB)
SSP022 Estradiol (Oestrogel® Pump-Pack 0.06% gel) 0.06% gel (750microgram per actuation) substitution (PDF:750KB)

19 May 2022 to 19 Aug 2022

This SSP has been varied – the revised date is now 28 October 2022

Oestrogel® supporting guidance plus Q&A (PDF:149KB)
SSP020 Ovestin® 1mg  cream restriction (PDF:166KB)

29 Apr 2022 to 29 Jul 2022

This SSP has been varied – the revised date is now 28 October 2022

Ovestin® supporting guidance plus Q&A (PDF:122KB)
SSP019 Oestrogel®  Pump-Pack 0.06% gel restriction (PDF:167KB)

29 Apr 2022 to 29 Jul 2022

This SSP has been varied – the revised date is now 28 October 2022

Oestrogel® supporting guidance plus Q&A (PDF:125KB)
SSP005 Fluoxetine 10mg tablets (PDF:134KB)

12 Mar 2020 to 31 Mar 2021

This SSP has been varied – the revised end date is now 12 August 2022

Please note that from 1 Feb 2022 for endorsement purposes the reference number of this SSP has been changed to SSP 005 to reflect updated guidance

Fluoxetine supporting guidance plus Q&A (PDF: 107KB)

 

Expired SSPs

Name of SSP \ ref no. Start and end date Supporting guidance
SSP021 Premique® low dose 0.3mg/1.5mg modified-release tablets (PDF:166KB) 29 Apr 2022 to 29 Jul 2022 Premique® low dose supporting guidance plus Q&A (PDF:122KB)
SSP018 Salazopyrin® 500mg tablets (PDF:244KB) 16 Mar 2022 to 25 Mar 2022 Salazopyrin® supporting guidance plus Q&A (PDF:112KB)
SSP017 Atorvastatin (Lipitor®) 20mg chewable tablets (PDF:122KB)

15 Feb 2022 to 5 Apr 2022

Atorvastatin supporting guidance plus Q&A (PDF:111KB)
SSP016 Atorvastatin (Lipitor®) 10mg chewable tablets (PDF:123KB)

15 Feb 2022 to 18 Mar 2022

Atorvastatin supporting guidance plus Q&A (PDF:111KB)
SSP015 Paracetamol 120mg and 240mg suppositories (PDF:124KB)

25 Jan 2022 to 4 Mar 2022

Paracetamol supporting guidance plus Q&A (PDF:111KB)
SSP014 Salazopyrin® 500mg EN tablets (PDF:160KB)

28 Feb 2022 to 1 Apr 2022 

This SSP was reactivated.
Salazopyrin® EN supporting guidance plus Q&A (PDF:111KB)
SSP014 Salazopyrin® 500mg EN tablets (PDF:160KB)

26 Nov 2021 to 21 Jan 2022

Salazopyrin® EN supporting guidance plus Q&A (PDF:135KB)
SSP013 Atorvastatin (Lipitor®) 20mg chewable tablets (PDF:211KB) 18 Nov 2021 to 12 Jan 2022 Atorvastatin supporting guidance plus Q&A (PDF: 134KB)
SSP012 Estradot®  75microgram patches (PDF:204KB)

29 Apr 2021 to 11 Jun 2021

Estradot®  supporting guidance plus Q&A (PDF: 120KB)
SSP011 Competact 15mg/850mg tablets (PDF:170KB)

24 Mar 2021 to 14 May 2021

Competact supporting guidance plus Q&A (PDF: 113KB)
SSP010 Levothyroxine 12.5microgram tablets (PDF:143KB)

3 Feb 2021 to 1 Apr 2021

Levothyroxine supporting guidance plus Q&A (PDF: 111KB)
SSP009 Fluoxetine 40mg capsules (PDF:139KB)

29 Jan 2021 to 17 May 2021

Fluoxetine supporting guidance plus Q&A (PDF: 111KB)
SSP008 Salazopyrin 500mg EN tablets (PDF:151KB)

20 Oct 2020 to 8 Mar 2021

Salazopyrin EN supporting guidance plus Q&A (PDF: 130KB)
SSP007 Fluoxetine 30mg capsules (PDF:144KB)

20 Oct 2020 to 28 Jul 2021

Fluoxetine supporting guidance plus Q&A (PDF: 142KB)
SSP06 Fluoxetine 40mg capsules (PDF:135KB) 20 May 2020 to 2 Oct 2020 Fluoxetine supporting guidance plus Q&A (PDF: 111KB)
SSP04 Haloperidol  (Serenace) 500 microgram (mcg) capsules (PDF:107KB) 23 Dec 2019 to 23 Mar 2020 Haloperidol supporting guidance plus Q&A (PDF:125KB)
SSP03 Fluoxetine 40mg capsules (PDF:131KB)

3 Oct 2019 to  20 Nov 2019

Fluoxetine supporting endorsement guidance (PDF: 139KB)
SSP02 Fluoxetine 30mg capsules (PDF:124KB)

3 Oct 2019 to 18 Dec 2019

This SSP has been varied - the revised end date is now 18 Dec 19, and supply in accordance with this SSP is now

1 x 10mg Fluoxetine capsule PLUS 1 x 20mg Fluoxetine capsule.

Fluoxetine supporting endorsement guidance (PDF: 139KB)
SSP01 Fluoxetine 10mg capsules (PDF:151KB)

3 Oct 2019 to 25 Oct 2019

Fluoxetine supporting endorsement guidance (PDF: 139KB)

 


General guidance for SSPs

Serious Shortage Protocols Operational Guidance (PDF:178KB)Serious Shortage Protocols Questions and Answers (PDF:173KB)